Effector Therapeutics has rallied marquee investors for a sizable $45 million Series A financing, determined to use discoveries in protein translation to mine for new cancer drugs.
For Amgen and Novartis, investing in the latest fund from Atlas Venture wasn't enough. The Cambridge, MA-based venture firm has struck separate agreements with the two major drugmakers to join forces on biotech startups.
Alnylam Pharmaceuticals CEO John Maraganore has joined Third Rock in the advisory role of venture partner, reunited in a way with his former Millennium Pharmaceuticals colleagues who launched the venture firm 6 years ago.
Frazier Healthcare has grabbed commitments of $281.8 million toward a targeted $300 million for the venture firm's seventh fund, according to an SEC filing. The firm seeks to raise half as much as the $600 million it secured for its previous fund launched in 2008, yet the crew at Frazier have done well enough to survive a serious drought fundraising for VC outfits.
The company plans to spend the capital on advancing a pipeline of vaccines, including a Phase II trial for a candidate called ProCervix for patients with high-risk cases of human papillomavirus (HPV) infection.
Ask any biotech exec in the business of drug and device development about the funding environment these days, and you'll most likely hear the word "tough" inside of three seconds. The...
Brace for more dour figures on venture investment in biotech. Despite some bright spots in life sciences venture investing, a new study finds that VC players in biotech and devices might struggle to sustain investment levels. And one of the few consolation prizes for the companies that won venture deals is that valuations inched up in 2012.
Elcelyx Therapeutics has landed a new investor as the biotech startup advances two lead products toward two major markets--weight management and diabetes.
The U.K.'s largest charity has already begun to pour some serious pounds into biotech startups. The Wellcome Trust has organized its efforts under a new venture unit called Syncona to back early-stage outfits in biotech and other healthcare sectors with an initial £200 million ($325 million) fund.
River Vision Development has wrapped up a $17 million first-round financing for a therapy that combats an illness that causes loss of vision and eyes to bulge from the socket. The lead backers include GlaxoSmithKline's venture unit SR One and Lundbeckfond Ventures.